Vaccination against Babesiosis

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (7 December 2022) | Viewed by 283

Special Issue Editor

E-Mail Website
Guest Editor
Centre de Biologie Structurale, INSERM U1054, CNRS UMR 5048, Université de Montpellier, 34090 Montpellier, France
Interests: structural basis of plant immunity; high pressure NMR; recombinant anti parasitic vaccines

Special Issue Information

Dear Colleagues, 

We wish to publish a Special Issue concerning the state of the art in the field of vaccination against Babesia.

We invite submissions in the form of original research papers or review papers on the topic of your choice in this area. Babesia and babesiosis as a widespread disease, with multiple clinical forms found in multiple host–parasite interactions, have been studied from multiple angles, and we hope to reflect this diversity in our Special Issue. This represents an opportunity to create an overview of current research that could be translated in efficient actions to control parasites in the field, both for human and animal populations.

As a proposal, and among other potential topics, we suggest papers concerning various host and parasite species, ranging from basic science to operational interventions in the field, with a focus on:

  • Current and future strategies to identify vaccine candidates and to define correlates of protection.
  • Knowledge from successful and unsuccessful Babesia vaccines: live, subunit or recombinant.
  • Stimulating molecules from the parasite: proteins are not alone...
  • Host response to infection: immune and physiopathological response.
  • Industrial and regulatory issues in Babesia vaccine market.
  • Cross-species immunity in Babesia; immune response against vectors. 

Dr. Stéphane Delbecq
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Babesia
  • vaccine
  • antigen
  • one health
  • immune escape mechanism
  • industrial production
  • protein structure
  • correlate of protection

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop